OnKure Therapeutics, Inc.
NASDAQ:OKURBiotechnology
+$0.01 today
- Market cap
- $114.22M
- Beta
- 0.28
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$4.30
Volume 0.17M
Average 0.37M
OKUR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
OnKure Therapeutics, Inc.NASDAQ: OKUR
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $15.16M (cash outflow) fell 4.8% year over year, ahead of the -23.5% change in trailing-twelve-month net income. Sequentially, it rose 12.2% from the prior quarter. Over 3 fiscal years it compounded at +26.3% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 3 analysts of -$37.69M (-36.7%) for the fiscal year ending Dec 2026, a slowdown from the +13.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$15.16M+12.2% QoQ
- Last fiscal yearDec 2025
- -$59.52M+13.0% YoY
- LTMMar 2026
- -$58.75M-23.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -4.8% | -40.5% | -35.6 pp |
| 1 year | +13.0% | -36.7% | -49.7 pp |
| 3-year CAGR | +26.3% | -20.7% | -47.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (59.52M) USD
- Year-over-year change
- -13.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (59.52M) | -13.0% |
| FY2024 | 2024-12-31 | (52.67M) | -49.2% |
| FY2023 | 2023-12-31 | (35.31M) | -19.6% |
| FY2022 | 2022-12-31 | (29.51M) | +25.8% |
| FY2021 | 2021-12-31 | (39.77M) | — |
Net Income vs competitors
How OKUR compares with its peers on the latest reported figures
- OKUR's LTM Mar 2026 net income of $58.75M is the 2nd largest of the 4 companies compared; the peer median is $11.31M.
- Its year-over-year change of -23.5% is the 3rd highest of 4, against a peer median of +127.6%.
- Over three fiscal years its annual growth of +26.3% compares with a peer median of +0.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $18.8B | +53055.5% | +845.2% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $58.75M | -23.5% | +26.3% | — |
| LTM Mar 2026 | $31.3M | -42.4% | -26.5% | 58.5% | |
| LTM Jun 2026 | $11.31M | +127.6% | +0.9% | 32.2% | |
| Peer median (excluding OKUR) | $11.31M | +127.6% | +0.9% | 45.4% | |
Competitors are the stored peer set for OKUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (39.77M) | (29.51M) | (35.31M) | (52.67M) | (59.52M) |
| Depreciation & Amortization | 50K | 387K | 560K | 662K | 830K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 48K | 199K | 4.53M | 11.63M |
| Change in Working Capital | (2.8M) | 2.12M | 6K | (3.95M) | (4.78M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 1.71M | (5.93M) | (4.55M) |
| Other Working Capital | (2.8M) | 2.12M | (1.71M) | 1.98M | (235K) |
| Other Non-Cash Items | 4.54M | 0 | 0 | 316K | 6K |
| Operating Cash Flow | (37.98M) | (26.95M) | (34.55M) | (51.12M) | (51.83M) |
| Capital Expenditures | (198K) | (1.13M) | (246K) | (52K) | (46K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (31.41M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.23M | 44.1M | 0 | 15.93M | 0 |
| Other Investing Activities | 0 | (44.1M) | 0 | 0 | 0 |
| Investing Cash Flow | (23.38M) | (1.13M) | (246K) | 15.87M | (46K) |
| Debt Repayment | 0 | 0 | 0 | 6M | 0 |
| Common Stock Issued | 132.41M | 340K | 65K | 58.91M | 203K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (1.38M) | (723K) | 51.22M | (40K) |
| Financing Cash Flow | 132.41M | 26.47M | 53.13M | 116.13M | 163K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 71.05M | (1.62M) | 18.33M | 80.89M | (51.71M) |
| Free Cash Flow | (38.18M) | (28.09M) | (34.79M) | (51.17M) | (51.87M) |
OnKure Therapeutics, Inc.
NASDAQ:OKUR
Intrinsic Alpha fair value
Locked
Current Price
$2.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.